A potent efficacy of pioglitazone on alcoholic and non-alcoholic fatty liver disease in type 2 diabetic mellitus - A potent efficacy of pioglitazone on alcoholic and non-alcoholic fatty liver disease in type 2 diabetic mellitus

In patients with fatty liver, the HbA1c, AST, ALT, and gGTP levels significantly decreased after pioglitazone treatment than before (P<0.01). The AST and ALT levels, but not the gGTP level, and the FIB-4 index significantly decreased after pioglitazone addition in the AFLD group, similar to that in the NAFLD group (P<0.05 and P<0.01, respectively). Similar effects were observed following low-dose pioglitazone treatment (below 7.5 mg/day) (P<0.05) in T2D patients with AFLD and NAFLD.